Skip to main content
Top
Gepubliceerd in:

01-06-2024 | Review

Health state utility values in patients with Ankylosing Spondylitis: a systematic review and meta-analysis

Auteurs: JunChao Feng, KunTing Zhang, Lei Dou, Zhao Shi, Gang Chen, Shunping Li

Gepubliceerd in: Quality of Life Research | Uitgave 9/2024

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail

Abstract

Introduction

Ankylosing spondylitis (AS) is a chronic condition that requires lifelong treatment and results in a serious disease burden. Health state utility values (HSUVs) are a valuable tool for quantifying this burden and conducting cost-utility analysis.

Objective

We conducted a systematic review and meta-analysis to obtain estimates of HSUVs in patients with AS, explored potential sources of heterogeneity, and compared pooled patient HSUVs with population norms.

Method

We searched PubMed, Embase, Web of science, Cochrane database and Scopus until July, 2023 to obtain eligible studies. The methodological quality of the included studies was assessed using the ROBINS-I checklist.

Results

Forty-two publications involving 11,354 participants were included in this systematic review. The most commonly used instrument is the EQ-5D (38 studies). The estimated HSUVs for patients with AS from all available studies was pooled as 0.62 (95% CI 0.59 to 0.65). The pooled mean utility estimates from the random effects meta-analysis for SF-6D, EQ-5D-3L, EQ-5D-5L, and HUI3 were 0.65 (95% CI 0.62,0.68), 0.63 (95% CI 0.59,0.66), 0.60 (95% CI 0.42,0.79), and 0.48 (95% CI 0.43,0.53), respectively. For the EQ-5D-3L we conducted stratified meta-analyses and meta-regression based on key subgroups. The pooled estimates of EQ-5D-3L were lower for patients published before 2010, with high disease activity, long duration of disease, and in developed countries.

Conclusion

Pooled estimates of HSUVs for people with AS were substantially lower than population norms. These estimates provide robust evidence that can inform the economic evaluation of new therapies for individuals with AS.
Bijlagen
Alleen toegankelijk voor geautoriseerde gebruikers
Literatuur
6.
go back to reference Yang, X., Fan, D., Xia, Q., Wang, M., Zhang, X., Li, X., Shengqian, X., & Pan, F. (2016). The health-related quality of life of ankylosing spondylitis patients assessed by SF-36: a systematic review and meta-analysis. Quality of Life Research: An International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation, 25(11), 2711–2723. https://doi.org/10.1007/s11136-016-1345-zCrossRefPubMed Yang, X., Fan, D., Xia, Q., Wang, M., Zhang, X., Li, X., Shengqian, X., & Pan, F. (2016). The health-related quality of life of ankylosing spondylitis patients assessed by SF-36: a systematic review and meta-analysis. Quality of Life Research: An International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation, 25(11), 2711–2723. https://​doi.​org/​10.​1007/​s11136-016-1345-zCrossRefPubMed
8.
go back to reference Ramiro, S., Nikiphorou, E., Sepriano, A., Ortolan, A., Webers, C., Baraliakos, X., Landewé, R. B. M., Van den Bosch, F. E., Boteva, B., Bremander, A., Carron, P., Ciurea, A., van Gaalen, F. A., Géher, P., Gensler, L., Hermann, J., de Hooge, M., Husakova, M., Kiltz, U., … van der Heijde, D. (2023). ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update. Annals of the Rheumatic Diseases, 82(1), 19–34. https://doi.org/10.1136/ard-2022-223296CrossRefPubMed Ramiro, S., Nikiphorou, E., Sepriano, A., Ortolan, A., Webers, C., Baraliakos, X., Landewé, R. B. M., Van den Bosch, F. E., Boteva, B., Bremander, A., Carron, P., Ciurea, A., van Gaalen, F. A., Géher, P., Gensler, L., Hermann, J., de Hooge, M., Husakova, M., Kiltz, U., … van der Heijde, D. (2023). ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update. Annals of the Rheumatic Diseases, 82(1), 19–34. https://​doi.​org/​10.​1136/​ard-2022-223296CrossRefPubMed
12.
go back to reference Wolowacz, S. E., Briggs, A., Belozeroff, V., Clarke, P., Doward, L., Goeree, R., Lloyd, A., & Norman, Ri. (2016). Estimating Health-State Utility for Economic Models in Clinical Studies: An ISPOR Good Research Practices Task Force Report. Value in Health: The Journal of the International Society for Pharmacoeconomics and Outcomes Research, 19(6), 704–719. https://doi.org/10.1016/j.jval.2016.06.001CrossRefPubMed Wolowacz, S. E., Briggs, A., Belozeroff, V., Clarke, P., Doward, L., Goeree, R., Lloyd, A., & Norman, Ri. (2016). Estimating Health-State Utility for Economic Models in Clinical Studies: An ISPOR Good Research Practices Task Force Report. Value in Health: The Journal of the International Society for Pharmacoeconomics and Outcomes Research, 19(6), 704–719. https://​doi.​org/​10.​1016/​j.​jval.​2016.​06.​001CrossRefPubMed
13.
go back to reference Chiowchanwisawakit, P., Thaweeratthakul, P., Wattanamongkolsil, L., Srinonprasert, V., Koolvisoot, A., Muangchan, C., Nilganuwong, S., Arromdee, E., & Katchamart, W. (2019). Relationship Between health-related quality of life and patient acceptable symptom state with disease activity and functional status in patients with ankylosing spondylitis in Thailand. Journal of Clinical Rheumatology, 25(1), 16–23. https://doi.org/10.1097/RHU.0000000000000750CrossRefPubMed Chiowchanwisawakit, P., Thaweeratthakul, P., Wattanamongkolsil, L., Srinonprasert, V., Koolvisoot, A., Muangchan, C., Nilganuwong, S., Arromdee, E., & Katchamart, W. (2019). Relationship Between health-related quality of life and patient acceptable symptom state with disease activity and functional status in patients with ankylosing spondylitis in Thailand. Journal of Clinical Rheumatology, 25(1), 16–23. https://​doi.​org/​10.​1097/​RHU.​0000000000000750​CrossRefPubMed
14.
20.
go back to reference de Kok, I. M. C. M., Korfage, I. J., van den Hout, W. B., Helmerhorst, T. J. M., Habbema, J. D. F., Essink-Bot, M.-L., & van Ballegooijen, M. (2018). Quality of life assumptions determine which cervical cancer screening strategies are cost-effective. International Journal of Cancer, 142(11), 2383–2393. https://doi.org/10.1002/ijc.31265CrossRefPubMed de Kok, I. M. C. M., Korfage, I. J., van den Hout, W. B., Helmerhorst, T. J. M., Habbema, J. D. F., Essink-Bot, M.-L., & van Ballegooijen, M. (2018). Quality of life assumptions determine which cervical cancer screening strategies are cost-effective. International Journal of Cancer, 142(11), 2383–2393. https://​doi.​org/​10.​1002/​ijc.​31265CrossRefPubMed
21.
go back to reference Brazier, J., Ara, R., Azzabi, I., Busschbach, J., Chevrou-Séverac, H., Crawford, B., Cruz, L., Karnon, J., Lloyd, A., Suzy Paisley, A., & Pickard, S. (2019). Identification, review, and use of health state utilities in cost-effectiveness models: An ISPOR good practices for outcomes research task force report. Value in Health: The Journal of the International Society for Pharmacoeconomics and Outcomes Research, 22(3), 267–275. https://doi.org/10.1016/j.jval.2019.01.004CrossRefPubMed Brazier, J., Ara, R., Azzabi, I., Busschbach, J., Chevrou-Séverac, H., Crawford, B., Cruz, L., Karnon, J., Lloyd, A., Suzy Paisley, A., & Pickard, S. (2019). Identification, review, and use of health state utilities in cost-effectiveness models: An ISPOR good practices for outcomes research task force report. Value in Health: The Journal of the International Society for Pharmacoeconomics and Outcomes Research, 22(3), 267–275. https://​doi.​org/​10.​1016/​j.​jval.​2019.​01.​004CrossRefPubMed
22.
go back to reference Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., Chou, R., Glanville, J., Grimshaw, J. M., Hróbjartsson, A., Lalu, M. M., Li, T., Loder, E. W., Mayo-Wilson, E., McDonald, S., … Moher, D. (2021). The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ, 372, n71. https://doi.org/10.1136/bmj.n71CrossRefPubMedPubMedCentral Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., Chou, R., Glanville, J., Grimshaw, J. M., Hróbjartsson, A., Lalu, M. M., Li, T., Loder, E. W., Mayo-Wilson, E., McDonald, S., … Moher, D. (2021). The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ, 372, n71. https://​doi.​org/​10.​1136/​bmj.​n71CrossRefPubMedPubMedCentral
28.
go back to reference Garrett, S., Jenkinson, T., Kennedy, L. G., Whitelock, H., Gaisford, P., & Calin, A. (1994). A new approach to defining disease status in ankylosing spondylitis: The bath ankylosing spondylitis disease activity index. The Journal of Rheumatology, 21(12), 2286–2291.PubMed Garrett, S., Jenkinson, T., Kennedy, L. G., Whitelock, H., Gaisford, P., & Calin, A. (1994). A new approach to defining disease status in ankylosing spondylitis: The bath ankylosing spondylitis disease activity index. The Journal of Rheumatology, 21(12), 2286–2291.PubMed
29.
go back to reference Van Tubergen, A., Boonen, A., Landewé, R., Rutten-Van Mölken, M., Van Der Heijde, D., Hidding, A., & Van Der Linden, S. (2002). Cost effectiveness of combined spa-exercise therapy in ankylosing spondylitis: A randomized controlled trial: Cost effectiveness of spa therapy in ankylosing spondylitis. Arthritis Care & Research, 47(5), 459–467. https://doi.org/10.1002/art.10658CrossRef Van Tubergen, A., Boonen, A., Landewé, R., Rutten-Van Mölken, M., Van Der Heijde, D., Hidding, A., & Van Der Linden, S. (2002). Cost effectiveness of combined spa-exercise therapy in ankylosing spondylitis: A randomized controlled trial: Cost effectiveness of spa therapy in ankylosing spondylitis. Arthritis Care & Research, 47(5), 459–467. https://​doi.​org/​10.​1002/​art.​10658CrossRef
32.
go back to reference Závada, J., Uher, M., Sisol, K., Forejtová, Š, Jarošová, K., Mann, H., Vencovský, J., & Pavelka, K. (2016). A tailored approach to reduce dose of anti-TNF drugs may be equally effective, but substantially less costly than standard dosing in patients with ankylosing spondylitis over 1 year: a propensity score-matched cohort study. Annals of the Rheumatic Diseases, 75(1), 96–102. https://doi.org/10.1136/annrheumdis-2014-205202CrossRefPubMed Závada, J., Uher, M., Sisol, K., Forejtová, Š, Jarošová, K., Mann, H., Vencovský, J., & Pavelka, K. (2016). A tailored approach to reduce dose of anti-TNF drugs may be equally effective, but substantially less costly than standard dosing in patients with ankylosing spondylitis over 1 year: a propensity score-matched cohort study. Annals of the Rheumatic Diseases, 75(1), 96–102. https://​doi.​org/​10.​1136/​annrheumdis-2014-205202CrossRefPubMed
33.
go back to reference Reveille, J. D., Hwang, M. C., Danve, A., Kafka, S., Peterson, S., Lo, K. H., Kim, L., Hsia, E. C., Chan, E. K. H., & Deodhar, A. (2021). The effect of intravenous golimumab on health-related quality of life and work productivity in adult patients with active ankylosing spondylitis: results of the phase 3 GO-ALIVE trial. Clinical Rheumatology, 40(4), 1331–1341. https://doi.org/10.1007/s10067-020-05342-7CrossRefPubMed Reveille, J. D., Hwang, M. C., Danve, A., Kafka, S., Peterson, S., Lo, K. H., Kim, L., Hsia, E. C., Chan, E. K. H., & Deodhar, A. (2021). The effect of intravenous golimumab on health-related quality of life and work productivity in adult patients with active ankylosing spondylitis: results of the phase 3 GO-ALIVE trial. Clinical Rheumatology, 40(4), 1331–1341. https://​doi.​org/​10.​1007/​s10067-020-05342-7CrossRefPubMed
34.
go back to reference Clemens, S., Begum, N., Harper, C., Whitty, J. A., & Scuffham, P. A. (2014). A comparison of EQ-5D-3L population norms in Queensland, Australia, estimated using utility value sets from Australia, the UK and USA. Quality of Life Research: An International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation, 23(8), 2375–2381. https://doi.org/10.1007/s11136-014-0676-xCrossRefPubMed Clemens, S., Begum, N., Harper, C., Whitty, J. A., & Scuffham, P. A. (2014). A comparison of EQ-5D-3L population norms in Queensland, Australia, estimated using utility value sets from Australia, the UK and USA. Quality of Life Research: An International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation, 23(8), 2375–2381. https://​doi.​org/​10.​1007/​s11136-014-0676-xCrossRefPubMed
35.
41.
go back to reference Walsh, J. A., Ogdie, A., Michaud, K., Peterson, S., Holdsworth, E. A., Karyekar, C. S., Booth, N., Middleton-Dalby, C., Chakravarty, S. D., Dennis, N., & Gossec, L. (2023). Impact of key manifestations of psoriatic arthritis on patient quality of life, functional status, and work productivity: Findings from a real-world study in the United States and Europe. Joint Bone Spine, 90(3), 105534. https://doi.org/10.1016/j.jbspin.2023.105534CrossRefPubMed Walsh, J. A., Ogdie, A., Michaud, K., Peterson, S., Holdsworth, E. A., Karyekar, C. S., Booth, N., Middleton-Dalby, C., Chakravarty, S. D., Dennis, N., & Gossec, L. (2023). Impact of key manifestations of psoriatic arthritis on patient quality of life, functional status, and work productivity: Findings from a real-world study in the United States and Europe. Joint Bone Spine, 90(3), 105534. https://​doi.​org/​10.​1016/​j.​jbspin.​2023.​105534CrossRefPubMed
43.
go back to reference Kiltz, U., & van der Heijde, D. (2009). Health-related quality of life in patients with rheumatoid arthritis and in patients with ankylosing spondylitis. Clinical and Experimental Rheumatology, 27(4 Suppl 55), S108-111.PubMed Kiltz, U., & van der Heijde, D. (2009). Health-related quality of life in patients with rheumatoid arthritis and in patients with ankylosing spondylitis. Clinical and Experimental Rheumatology, 27(4 Suppl 55), S108-111.PubMed
45.
go back to reference Balázs, P. G., Erdősi, D., Zemplényi, A., & Brodszky, V. (2023). Time trade-off health state utility values for depression: A systematic review and meta-analysis. Quality of Life Research: An International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation, 32(4), 923–937. https://doi.org/10.1007/s11136-022-03253-5CrossRefPubMed Balázs, P. G., Erdősi, D., Zemplényi, A., & Brodszky, V. (2023). Time trade-off health state utility values for depression: A systematic review and meta-analysis. Quality of Life Research: An International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation, 32(4), 923–937. https://​doi.​org/​10.​1007/​s11136-022-03253-5CrossRefPubMed
47.
go back to reference Zochling, J. (2011). Measures of symptoms and disease status in ankylosing spondylitis: Ankylosing Spondylitis Disease Activity Score (ASDAS), Ankylosing Spondylitis Quality of Life Scale (ASQoL), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing Spondylitis Functional Index (BASFI), Bath Ankylosing Spondylitis Global Score (BAS-G), Bath Ankylosing Spondylitis Metrology Index (BASMI), Dougados Functional Index (DFI), and Health Assessment Questionnaire for the Spondylarthropathies (HAQ-S). Arthritis Care & Research, 63(Suppl 11), S47-58. https://doi.org/10.1002/acr.20575CrossRef Zochling, J. (2011). Measures of symptoms and disease status in ankylosing spondylitis: Ankylosing Spondylitis Disease Activity Score (ASDAS), Ankylosing Spondylitis Quality of Life Scale (ASQoL), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing Spondylitis Functional Index (BASFI), Bath Ankylosing Spondylitis Global Score (BAS-G), Bath Ankylosing Spondylitis Metrology Index (BASMI), Dougados Functional Index (DFI), and Health Assessment Questionnaire for the Spondylarthropathies (HAQ-S). Arthritis Care & Research, 63(Suppl 11), S47-58. https://​doi.​org/​10.​1002/​acr.​20575CrossRef
51.
go back to reference Zhou, T., Guan, H., Yao, J., Xiong, X., & Ma, A. (2018). The quality of life in Chinese population with chronic non-communicable diseases according to EQ-5D-3L: A systematic review. Quality of Life Research: An International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation, 27(11), 2799–2814. https://doi.org/10.1007/s11136-018-1928-yCrossRefPubMed Zhou, T., Guan, H., Yao, J., Xiong, X., & Ma, A. (2018). The quality of life in Chinese population with chronic non-communicable diseases according to EQ-5D-3L: A systematic review. Quality of Life Research: An International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation, 27(11), 2799–2814. https://​doi.​org/​10.​1007/​s11136-018-1928-yCrossRefPubMed
52.
go back to reference Kennedy-Martin, M., Slaap, B., Herdman, M., van Reenen, M., Kennedy-Martin, T., Greiner, W., Busschbach, J., & Boye, K. S. (2020). Which multi-attribute utility instruments are recommended for use in cost-utility analysis? A review of national health technology assessment (HTA) guidelines. The European journal of health economics: HEPAC: health economics in prevention and care, 21(8), 1245–1257. https://doi.org/10.1007/s10198-020-01195-8CrossRefPubMed Kennedy-Martin, M., Slaap, B., Herdman, M., van Reenen, M., Kennedy-Martin, T., Greiner, W., Busschbach, J., & Boye, K. S. (2020). Which multi-attribute utility instruments are recommended for use in cost-utility analysis? A review of national health technology assessment (HTA) guidelines. The European journal of health economics: HEPAC: health economics in prevention and care, 21(8), 1245–1257. https://​doi.​org/​10.​1007/​s10198-020-01195-8CrossRefPubMed
54.
go back to reference Richardson, J., Iezzi, A., & Khan, M. A. (2015). Why do multi-attribute utility instruments produce different utilities: The relative importance of the descriptive systems, scale and “micro-utility” effects. Quality of Life Research: An International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation, 24(8), 2045–2053. https://doi.org/10.1007/s11136-015-0926-6CrossRefPubMed Richardson, J., Iezzi, A., & Khan, M. A. (2015). Why do multi-attribute utility instruments produce different utilities: The relative importance of the descriptive systems, scale and “micro-utility” effects. Quality of Life Research: An International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation, 24(8), 2045–2053. https://​doi.​org/​10.​1007/​s11136-015-0926-6CrossRefPubMed
57.
go back to reference Kiltz, U., van der Heijde, D., Boonen, A., & Braun, J. (2014). The ASAS health index (ASAS HI) - a new tool to assess the health status of patients with spondyloarthritis. Clinical and Experimental Rheumatology, 32(5 Suppl 85), S-105-108. Kiltz, U., van der Heijde, D., Boonen, A., & Braun, J. (2014). The ASAS health index (ASAS HI) - a new tool to assess the health status of patients with spondyloarthritis. Clinical and Experimental Rheumatology, 32(5 Suppl 85), S-105-108.
63.
go back to reference Heiberg, M. S., Nordvåg, B. Y., Mikkelsen, K., Rødevand, E., Kaufmann, C., Mowinckel, P., & Kvien, T. K. (2005). The comparative effectiveness of tumor necrosis factor-blocking agents in patients with rheumatoid arthritis and patients with ankylosing spondylitis: A six-month, longitudinal, observational, multicenter study. Arthritis and Rheumatism, 52(8), 2506–2512. https://doi.org/10.1002/art.21209CrossRefPubMed Heiberg, M. S., Nordvåg, B. Y., Mikkelsen, K., Rødevand, E., Kaufmann, C., Mowinckel, P., & Kvien, T. K. (2005). The comparative effectiveness of tumor necrosis factor-blocking agents in patients with rheumatoid arthritis and patients with ankylosing spondylitis: A six-month, longitudinal, observational, multicenter study. Arthritis and Rheumatism, 52(8), 2506–2512. https://​doi.​org/​10.​1002/​art.​21209CrossRefPubMed
70.
go back to reference Kvamme, M. K., Kristiansen, I. S., Lie, E., & Kvien, T. K. (2010). Identification of cutpoints for acceptable health status and important improvement in patient-reported outcomes, in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. The Journal of Rheumatology, 37(1), 26–31. https://doi.org/10.3899/jrheum.090449CrossRefPubMed Kvamme, M. K., Kristiansen, I. S., Lie, E., & Kvien, T. K. (2010). Identification of cutpoints for acceptable health status and important improvement in patient-reported outcomes, in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. The Journal of Rheumatology, 37(1), 26–31. https://​doi.​org/​10.​3899/​jrheum.​090449CrossRefPubMed
72.
go back to reference Kimel, M., Revicki, D., Rao, S., Fryback, D., Feeny, D., Harnam, N., Thompson, C., & Cifaldi, M. (2011). Norms-based assessment of patient-reported outcomes associated with adalimumab monotherapy in patients with ankylosing spondylitis. Clinical and Experimental Rheumatology, 29(4), 624–632.PubMed Kimel, M., Revicki, D., Rao, S., Fryback, D., Feeny, D., Harnam, N., Thompson, C., & Cifaldi, M. (2011). Norms-based assessment of patient-reported outcomes associated with adalimumab monotherapy in patients with ankylosing spondylitis. Clinical and Experimental Rheumatology, 29(4), 624–632.PubMed
78.
go back to reference Meesters, J. J. L., Petersson, I. F., Bergman, S., Haglund, E., Jacobsson, L. T. H., & Bremander, A. (2014). Sociodemographic and disease-related factors are associated with patient-reported anxiety and depression in spondyloarthritis patients in the Swedish SpAScania cohort. Clinical Rheumatology, 33(11), 1649–1656. https://doi.org/10.1007/s10067-014-2699-7CrossRefPubMed Meesters, J. J. L., Petersson, I. F., Bergman, S., Haglund, E., Jacobsson, L. T. H., & Bremander, A. (2014). Sociodemographic and disease-related factors are associated with patient-reported anxiety and depression in spondyloarthritis patients in the Swedish SpAScania cohort. Clinical Rheumatology, 33(11), 1649–1656. https://​doi.​org/​10.​1007/​s10067-014-2699-7CrossRefPubMed
79.
go back to reference Oliveira Junior, H. A. D., Almeida, A. M., Acurcio, F. A., Santos, J. B. D., Kakehasi, A. M., Alvares, J., Gomes e Souza Dabés, C., & Cherchiglia, M. L. (2015). Profile of patients with rheumatic diseases undergoing treatment with anti-TNF agents in the Brazilian Public Health System (SUS), Belo Horizonte - MG. Brazilian Journal of Pharmaceutical Sciences, 51(3), 709–719. https://doi.org/10.1590/S1984-82502015000300023CrossRef Oliveira Junior, H. A. D., Almeida, A. M., Acurcio, F. A., Santos, J. B. D., Kakehasi, A. M., Alvares, J., Gomes e Souza Dabés, C., & Cherchiglia, M. L. (2015). Profile of patients with rheumatic diseases undergoing treatment with anti-TNF agents in the Brazilian Public Health System (SUS), Belo Horizonte - MG. Brazilian Journal of Pharmaceutical Sciences, 51(3), 709–719. https://​doi.​org/​10.​1590/​S1984-8250201500030002​3CrossRef
80.
go back to reference Wallman, J. K., Kapetanovic, M. C., Petersson, I. F., Geborek, P., & Kristensen, L. E. (2015). Comparison of non-radiographic axial spondyloarthritis and ankylosing spondylitis patients—baseline characteristics, treatment adherence, and development of clinical variables during three years of anti-TNF therapy in clinical practice. Arthritis Research & Therapy, 17(1), 378. https://doi.org/10.1186/s13075-015-0897-6CrossRef Wallman, J. K., Kapetanovic, M. C., Petersson, I. F., Geborek, P., & Kristensen, L. E. (2015). Comparison of non-radiographic axial spondyloarthritis and ankylosing spondylitis patients—baseline characteristics, treatment adherence, and development of clinical variables during three years of anti-TNF therapy in clinical practice. Arthritis Research & Therapy, 17(1), 378. https://​doi.​org/​10.​1186/​s13075-015-0897-6CrossRef
82.
go back to reference Damjanov, N., Shehhi, W. A., Huang, F., Kotak, S., Burgos-Vargas, R., Shirazy, K., Bananis, E., Szumski, A., Llamado, L. J. Q., & Mahgoub, E. (2016). Assessment of clinical efficacy and safety in a randomized double-blind study of etanercept and sulfasalazine in patients with ankylosing spondylitis from Eastern/Central Europe, Latin America, and Asia. Rheumatology International, 36(5), 643–651. https://doi.org/10.1007/s00296-016-3452-0CrossRefPubMed Damjanov, N., Shehhi, W. A., Huang, F., Kotak, S., Burgos-Vargas, R., Shirazy, K., Bananis, E., Szumski, A., Llamado, L. J. Q., & Mahgoub, E. (2016). Assessment of clinical efficacy and safety in a randomized double-blind study of etanercept and sulfasalazine in patients with ankylosing spondylitis from Eastern/Central Europe, Latin America, and Asia. Rheumatology International, 36(5), 643–651. https://​doi.​org/​10.​1007/​s00296-016-3452-0CrossRefPubMed
83.
go back to reference Mlcoch, T., Sedova, L., Stolfa, J., Urbanova, M., Suchy, D., Smrzova, A., Jircikova, J., Pavelka, K., & Dolezal, T. (2017). Mapping the relationship between clinical and quality-of-life outcomes in patients with ankylosing spondylitis. Expert Review of Pharmacoeconomics & Outcomes Research, 17(2), 203–211. https://doi.org/10.1080/14737167.2016.1200468CrossRef Mlcoch, T., Sedova, L., Stolfa, J., Urbanova, M., Suchy, D., Smrzova, A., Jircikova, J., Pavelka, K., & Dolezal, T. (2017). Mapping the relationship between clinical and quality-of-life outcomes in patients with ankylosing spondylitis. Expert Review of Pharmacoeconomics & Outcomes Research, 17(2), 203–211. https://​doi.​org/​10.​1080/​14737167.​2016.​1200468CrossRef
85.
go back to reference Bredin, S., Fabre-Aubrespy, M., Blondel, B., Falguières, J., Schuller, S., Walter, A., Fuentes, S., Tropiano, P., Steib, J. P., & Charles, Y. P. (2017). Percutaneous surgery for thoraco-lumbar fractures in ankylosing spondylitis: Study of 31 patients. Orthopaedics & Traumatology, Surgery & Research: OTSR, 103(8), 1235–1239. https://doi.org/10.1016/j.otsr.2017.07.023CrossRef Bredin, S., Fabre-Aubrespy, M., Blondel, B., Falguières, J., Schuller, S., Walter, A., Fuentes, S., Tropiano, P., Steib, J. P., & Charles, Y. P. (2017). Percutaneous surgery for thoraco-lumbar fractures in ankylosing spondylitis: Study of 31 patients. Orthopaedics & Traumatology, Surgery & Research: OTSR, 103(8), 1235–1239. https://​doi.​org/​10.​1016/​j.​otsr.​2017.​07.​023CrossRef
86.
go back to reference Mease, P. J., Heijde, D. V. D., Karki, C., Palmer, J. B., Liu, M., Pandurengan, R., Park, Y., & Greenberg, J. D. (2018). Characterization of patients with ankylosing spondylitis and nonradiographic axial spondyloarthritis in the US -based corrona registry. Arthritis Care & Research, 70(11), 1661–1670. https://doi.org/10.1002/acr.23534CrossRef Mease, P. J., Heijde, D. V. D., Karki, C., Palmer, J. B., Liu, M., Pandurengan, R., Park, Y., & Greenberg, J. D. (2018). Characterization of patients with ankylosing spondylitis and nonradiographic axial spondyloarthritis in the US -based corrona registry. Arthritis Care & Research, 70(11), 1661–1670. https://​doi.​org/​10.​1002/​acr.​23534CrossRef
87.
go back to reference Salaffi, F., Di Carlo, M., Carotti, M., Farah, S., Ciapetti, A., & Gutierrez, M. (2019). The impact of different rheumatic diseases on health-related quality of life: a comparison with a selected sample of healthy individuals using SF-36 questionnaire, EQ-5D and SF-6D utility values. Acta Bio-Medica: Atenei Parmensis, 89(4), 541–557. https://doi.org/10.23750/abm.v89i4.7298CrossRefPubMed Salaffi, F., Di Carlo, M., Carotti, M., Farah, S., Ciapetti, A., & Gutierrez, M. (2019). The impact of different rheumatic diseases on health-related quality of life: a comparison with a selected sample of healthy individuals using SF-36 questionnaire, EQ-5D and SF-6D utility values. Acta Bio-Medica: Atenei Parmensis, 89(4), 541–557. https://​doi.​org/​10.​23750/​abm.​v89i4.​7298CrossRefPubMed
88.
go back to reference Min, H. K., Lee, J., Ju, J. H., Park, S. H., & Kwok, S. K. (2019). Predictors of assessment of spondyloarthritis international society (ASAS) health index in axial spondyloarthritis and comparison of ASAS health index between ankylosing spondylitis and nonradiographic axial spondyloarthritis: Data from the catholic axial spondyloarthritis cohort (CASCO). Journal of Clinical Medicine, 8(4), 467. https://doi.org/10.3390/jcm8040467CrossRefPubMedPubMedCentral Min, H. K., Lee, J., Ju, J. H., Park, S. H., & Kwok, S. K. (2019). Predictors of assessment of spondyloarthritis international society (ASAS) health index in axial spondyloarthritis and comparison of ASAS health index between ankylosing spondylitis and nonradiographic axial spondyloarthritis: Data from the catholic axial spondyloarthritis cohort (CASCO). Journal of Clinical Medicine, 8(4), 467. https://​doi.​org/​10.​3390/​jcm8040467CrossRefPubMedPubMedCentral
89.
go back to reference de Oliveira, Alves, Junior, H., Pereira da Veiga, T., Acurcio, F. D. A., Almeida, A. M., Ribeiro Dos Santos, J. B., da Silva, M. R. R., Kakehasi, A. M., & Cherchiglia, M. L. (2020). Impact of biologic DMARDs on quality of life: 12-month results of a rheumatic diseases cohort using the Brazilian EQ-5D tariff. Hospital Practice, 48(4), 213–222. https://doi.org/10.1080/21548331.2020.1785212CrossRef de Oliveira, Alves, Junior, H., Pereira da Veiga, T., Acurcio, F. D. A., Almeida, A. M., Ribeiro Dos Santos, J. B., da Silva, M. R. R., Kakehasi, A. M., & Cherchiglia, M. L. (2020). Impact of biologic DMARDs on quality of life: 12-month results of a rheumatic diseases cohort using the Brazilian EQ-5D tariff. Hospital Practice, 48(4), 213–222. https://​doi.​org/​10.​1080/​21548331.​2020.​1785212CrossRef
92.
go back to reference Strand, V., Deodhar, A., Alten, R., Sullivan, E., Blackburn, S., Tian, H., Gandhi, K. K., Jugl, S. M., & Conaghan, P. G. (2021). Pain and fatigue in patients with ankylosing spondylitis treated with tumor necrosis factor inhibitors: Multinational real-world findings. JCR:Journal of Clinical Rheumatology, 27(8), e446–e455. https://doi.org/10.1097/RHU.0000000000001544CrossRefPubMed Strand, V., Deodhar, A., Alten, R., Sullivan, E., Blackburn, S., Tian, H., Gandhi, K. K., Jugl, S. M., & Conaghan, P. G. (2021). Pain and fatigue in patients with ankylosing spondylitis treated with tumor necrosis factor inhibitors: Multinational real-world findings. JCR:Journal of Clinical Rheumatology, 27(8), e446–e455. https://​doi.​org/​10.​1097/​RHU.​0000000000001544​CrossRefPubMed
93.
go back to reference Van Der Zee-Neuen, A., Strobl, V., Dobias, H., Fuchs, J., Untner, J., Foisner, W., Knapp, M., Edtinger, S., Offenbächer, M., Ritter, M., Hölzl, B., & Gaisberger, M. (2022). Sustained improvements in EQ-5D utility scores and self-rated health status in patients with ankylosing spondylitis after spa treatment including low-dose radon—an analysis of prospective radon indication registry data. BMC Musculoskeletal Disorders, 23(1), 743. https://doi.org/10.1186/s12891-022-05691-1CrossRefPubMedPubMedCentral Van Der Zee-Neuen, A., Strobl, V., Dobias, H., Fuchs, J., Untner, J., Foisner, W., Knapp, M., Edtinger, S., Offenbächer, M., Ritter, M., Hölzl, B., & Gaisberger, M. (2022). Sustained improvements in EQ-5D utility scores and self-rated health status in patients with ankylosing spondylitis after spa treatment including low-dose radon—an analysis of prospective radon indication registry data. BMC Musculoskeletal Disorders, 23(1), 743. https://​doi.​org/​10.​1186/​s12891-022-05691-1CrossRefPubMedPubMedCentral
Metagegevens
Titel
Health state utility values in patients with Ankylosing Spondylitis: a systematic review and meta-analysis
Auteurs
JunChao Feng
KunTing Zhang
Lei Dou
Zhao Shi
Gang Chen
Shunping Li
Publicatiedatum
01-06-2024
Uitgeverij
Springer International Publishing
Gepubliceerd in
Quality of Life Research / Uitgave 9/2024
Print ISSN: 0962-9343
Elektronisch ISSN: 1573-2649
DOI
https://doi.org/10.1007/s11136-024-03670-8